Your browser doesn't support javascript.
loading
Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients.
Messchendorp, A Lianne; Sanders, Jan-Stephan F; Abrahams, Alferso C; Bemelman, Frederike J; Bouwmans, Pim; van den Dorpel, René M A; Hilbrands, Luuk B; Imhof, Céline; Reinders, Marlies E J; Rispens, Theo; Steenhuis, Maurice; Ten Dam, Marc A G J; Vart, Priya; de Vries, Aiko P J; Hemmelder, Marc H; Gansevoort, Ron T.
Affiliation
  • Messchendorp AL; Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
  • Sanders JF; Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
  • Abrahams AC; Department of Nephrology and Hypertension, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands.
  • Bemelman FJ; Division of Nephrology, Department of Internal Medicine, Amsterdam University Medical Center, Location Amsterdam Medical Center, 1105 AZ Amsterdam, The Netherlands.
  • Bouwmans P; Department of Internal Medicine, Division of Nephrology, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands.
  • van den Dorpel RMA; CARIM School for Cardiovascular Disease, University of Maastricht, 6211 LK Maastricht, The Netherlands.
  • Hilbrands LB; Department of Nephrology, Maasstad Hospital, 3079 DZ Rotterdam, The Netherlands.
  • Imhof C; Department of Nephrology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
  • Reinders MEJ; Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
  • Rispens T; Erasmus MC Transplant Institute, Nephrology and Transplantation, Department of Internal Medicine, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
  • Steenhuis M; Department of Immunopathology, Sanquin Research, 1006 AD Amsterdam, The Netherlands.
  • Ten Dam MAGJ; Landsteiner Laboratory, Amsterdam University Medical Center, University of Amsterdam, 1012 WP Amsterdam, The Netherlands.
  • Vart P; Department of Immunopathology, Sanquin Research, 1006 AD Amsterdam, The Netherlands.
  • de Vries APJ; Landsteiner Laboratory, Amsterdam University Medical Center, University of Amsterdam, 1012 WP Amsterdam, The Netherlands.
  • Hemmelder MH; Department of Internal Medicine, Canisius Wilhelmina Hospital, 6532 SZ Nijmegen, The Netherlands.
  • Gansevoort RT; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
  • Recovac Investigators; Leiden University Medical Center, Department of Nephrology and Leiden Transplant Center, 2333 ZA Leiden, The Netherlands.
Viruses ; 16(1)2024 01 12.
Article in En | MEDLINE | ID: mdl-38257814
ABSTRACT
Kidney transplant recipients (KTRs) elicit an impaired immune response after COVID-19 vaccination; however, the exact clinical impact remains unclear. We therefore analyse the relationship between antibody levels after vaccination and the risk of COVID-19 in a large cohort of KTRs. All KTRs living in the Netherlands were invited to send a blood sample 28 days after their second COVID-19 vaccination for measurement of their IgG antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein (anti-RBD IgG). Information on COVID-19 was collected from the moment the blood sample was obtained until 6 months thereafter. Multivariable Cox and logistic regression analyses were performed to analyse which factors affected the occurrence and severity (i.e., hospitalization and/or death) of COVID-19. In total, 12,159 KTRs were approached, of whom 2885 were included in the analyses. Among those, 1578 (54.7%) became seropositive (i.e., anti-RBD IgG level >50 BAU/mL). Seropositivity was associated with a lower risk for COVID-19, also after adjusting for multiple confounders, including socio-economic status and adherence to COVID-19 restrictions (HR 0.37 (0.19-0.47), p = 0.005). When studied on a continuous scale, we observed a log-linear relationship between antibody level and the risk for COVID-19 (HR 0.52 (0.31-0.89), p = 0.02). Similar results were found for COVID-19 severity. In conclusion, antibody level after COVID-19 vaccination is associated in a log-linear manner with the occurrence and severity of COVID-19 in KTRs. This implies that if future vaccinations are indicated, the aim should be to reach for as high an antibody level as possible and not only seropositivity to protect this vulnerable patient group from disease.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 / 2_ODS3 / 4_TD / 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Kidney Transplantation / Spike Glycoprotein, Coronavirus / COVID-19 Type of study: Incidence_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Viruses Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 / 2_ODS3 / 4_TD / 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Kidney Transplantation / Spike Glycoprotein, Coronavirus / COVID-19 Type of study: Incidence_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Viruses Year: 2024 Document type: Article